A Strategic Bet on Pulmonary Hypertension
GSK has struck a deal to acquire 35Pharma, a biotechnology company specializing in treatments for pulmonary hypertension, for $950 million. The acquisition represents one of the largest biopharma deals of 2026 so far and signals GSK's strategic intent to strengthen its position in respiratory and cardiovascular disease — areas where the London-based pharmaceutical giant has historically been a major player.
Pulmonary hypertension is a serious, progressive condition characterized by abnormally high blood pressure in the arteries of the lungs. The elevated pressure forces the right side of the heart to work harder to pump blood through the lungs, eventually leading to right heart failure if untreated. The disease affects an estimated 50 to 70 million people globally across its various forms, though exact prevalence figures are difficult to pin down because the condition is frequently underdiagnosed.
Current treatments can slow the progression of the disease and improve symptoms, but they do not cure it. Most patients require lifelong therapy with one or more medications, and many eventually face the need for lung transplantation. The market for pulmonary hypertension drugs is substantial — valued at approximately $8 billion annually — but significant unmet medical need remains, particularly in forms of the disease that do not respond well to existing therapies.
What 35Pharma Brings to GSK
35Pharma's pipeline includes both clinical-stage and preclinical programs targeting novel biological pathways involved in pulmonary hypertension. The company's lead candidate is in late-stage clinical trials and has shown promising efficacy data in patient populations with limited treatment options. Details about the specific mechanism of action and trial results were not fully disclosed in the acquisition announcement, but industry analysts have described the data as compelling enough to justify the premium valuation.
Beyond the lead program, 35Pharma has built a research platform focused on understanding the cellular and molecular mechanisms that drive pulmonary vascular remodeling — the process by which the walls of the pulmonary arteries thicken and stiffen, progressively narrowing the vessels and driving up blood pressure. This platform has generated a portfolio of preclinical assets that target different aspects of the remodeling process, giving GSK multiple shots on goal in a disease area with significant commercial potential.
The acquisition also brings specialized expertise. 35Pharma has assembled a team of researchers and clinicians with deep knowledge of pulmonary hypertension biology and drug development, including experience running clinical trials in a patient population that can be difficult to recruit and manage. This expertise will be valuable as GSK integrates the pipeline and advances programs through clinical development.
